ReviewDrug design, development and therapy2023
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations.
Review in Drug design, development and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Efficacy and safety of tebentafusp in patients with metastatic uveal melanoma: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2024Pooled it
- Review
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- A Brief Overview of Uveal Melanoma Treatment Methods with a Focus on the Latest Advances.Journal of clinical medicine · 2025Article
- Current Therapies and Potential Strategies for Uveal Melanoma.Drugs and drug candidates · 2025Article
- Significance of Aneuploidy in Predicting Prognosis and Treatment Response of Uveal Melanoma.Current medicinal chemistry · 2025Article
- Advances in immunotherapy for uveal melanoma: enhancing efficacy and overcoming resistance.Frontiers in cell and developmental biology · 2025Review
- Hepatic chemosaturation with melphalan in patients with primary or secondary liver tumors with or without extrahepatic tumor manifestation.ESMO gastrointestinal oncology · 2024Article
- GP100 expression is variable in intensity in melanoma.Cancer immunology, immunotherapy : CII · 2024Article
- IL-7-primed bystander CD8 tumor-infiltrating lymphocytes optimize the antitumor efficacy of T cell engager immunotherapy.Cell reports. Medicine · 2024Article
- Pityriasis lichenoides et varioliformis acuta in a patient treated with cevostamab.JAAD case reports · 2024Article
- Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.Frontiers in immunology · 2024Article
- Interdependence of Molecular Lesions That Drive Uveal Melanoma Metastasis.International journal of molecular sciences · 2023Article
- Genetic and Epigenetic Features of Uveal Melanoma-An Overview and Clinical Implications.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uveal melanoma (UM) is a rare type of melanoma with distinct features from cutaneous melanoma, low response rates to immune checkpoint inhibition, and poor survival rates. Tebentafusp, a bispecific antibody engaging T cells with gp 100 on HLA-A*02:01, was recently approved by the FDA as the first drug of its class and the first treatment approved by the FDA to treat UM. In this review, we summarize the preclinical and clinical data on tebentafusp for UM. We additionally discuss patient selection and the relevant challenges. For the literature search, PubMed search and relevant articles presented at international conferences were used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.